Evidence map›Paper›PMID 29429869›Full record

ReviewThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2018

Pharmacogenetic Decision Support Tools: A New Paradigm for Late-Life Depression?

Ryan Abbott, Donald D Chang, Harris A Eyre, Chad A Bousman, David A Merrill, Helen Lavretsky

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Ryan AbbottSchool of Law, University of Surrey, Guildford, UK; Department of Medicine for Abbott, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. Electronic address: r.abbott@surrey.ac.uk.
Donald D ChangSchool of Medicine, Ochsner Clinical School, University of Queensland, Brisbane, Queensland, Australia.
Harris A EyreTexas Medical Center Innovation Institute, Houston, TX, USA; Department of Psychiatry, Deakin University, Geelong, Victoria, Australia; Department of Psychiatry, University of Adelaide, Adelaide, South Australia, Australia; Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia.
Chad A BousmanDepartment of Psychiatry, Melbourne Neuropsychiatry Centre, University of Melbourne, Victoria, Australia.
David A MerrillDepartment of Psychiatry, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Helen LavretskyDepartment of Psychiatry, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
University of California, Los Angeles · USDeakin University · AUUniversity of Melbourne · AUUniversity of Queensland · AUUniversity of Surrey · GB

Funding

Brain connectivity and response to Tai Chi in geriatric depressionR01AT008383 · NCCIH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LAVRETSKY, HELEN · 2015 to 2019
$4.1M
Brain aging and treatment response in geriatric depressionR01MH097892 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LAVRETSKY, HELEN · 2013 to 2017
$3.5M
Mentoring and Research in Translational Science of Integrative MedicineK24AT009198 · NCCIH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Helen Lavretsky · 2016 to 2026
$1.4M
Neurobiological Mechanisms of Treatment Response in Geriatric DepressionK24MH086481 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LAVRETSKY, HELEN · 2010 to 2014
$906k
NCCIH NIH HHS K24 AT009198NCCIH NIH HHS R01 AT008383NIMH NIH HHS K24 MH086481NIMH NIH HHS R01 MH097892
6 · The paper itself

Abstract

Clinicians still employ a "trial-and-error" approach to optimizing treatment regimens for late-life depression (LLD). With LLD affecting a significant and growing segment of the population, and with only about half of older adults responsive to antidepressant therapy, there is an urgent need for a better treatment paradigm. Pharmacogenetic decision support tools (DSTs), which are emerging technologies that aim to provide clinically actionable information based on a patient's genetic profile, offer a promising solution. Dozens of DSTs have entered the market in the past 15 years, but with varying level of empirical evidence to support their value. In this clinical review, we provide a critical analysis of the peer-reviewed literature on DSTs for major depression management. We then discuss clinical considerations for the use of these tools in treating LLD, including issues related to test interpretation, timing, and patient perspectives. In adult populations, newer generation DSTs show promise for the treatment of major depression. However, there are no primary clinical trials in LLD cohorts. Independent and comparative clinical trials are needed.

Indexed as

AgingDecision Support TechniquesHumansMajor Depressive DisorderPharmacogeneticsPrecision Medicinedecision support toolDepressiongenetic testinggeriatriclate-life depressionpharmacogenomicprecision medicine

Identifiers

PMID29429869
PMCPMC5812821
OpenAlexW2618556664

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.